Cargando…

Post-marketing safety surveillance of the rotavirus vaccine in India

BACKGROUND: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India. METHODS: Observational, active PMS was conducted in approxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Gagandeep, Lakhkar, Anand, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Narwadkar, Jyoti, Kanujia, Arti, Desai, Sajjad, Gunale, Bhagwat, Poonawalla, Cyrus S., Kulkarni, Prasad S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430202/
https://www.ncbi.nlm.nih.gov/pubmed/37593522
http://dx.doi.org/10.1016/j.jvacx.2023.100362
_version_ 1785090904352096256
author Kang, Gagandeep
Lakhkar, Anand
Bhamare, Chetanraj
Dharmadhikari, Abhijeet
Narwadkar, Jyoti
Kanujia, Arti
Desai, Sajjad
Gunale, Bhagwat
Poonawalla, Cyrus S.
Kulkarni, Prasad S.
author_facet Kang, Gagandeep
Lakhkar, Anand
Bhamare, Chetanraj
Dharmadhikari, Abhijeet
Narwadkar, Jyoti
Kanujia, Arti
Desai, Sajjad
Gunale, Bhagwat
Poonawalla, Cyrus S.
Kulkarni, Prasad S.
author_sort Kang, Gagandeep
collection PubMed
description BACKGROUND: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India. METHODS: Observational, active PMS was conducted in approximately 10,000 infants aged ≥ 6 weeks. ROTASIIL was administered as a 3-dose regimen, at least 4 weeks apart, beginning at ≥ 6 weeks of age concomitantly with other Expanded Programme on Immunization (EPI) vaccines. Participants were followed for one month after the last dose. The adverse events (AEs) and serious adverse events (SAEs), including intussusception (IS) reported during the follow up period were collected. FINDINGS: A total of 9940 infants were enrolled and were considered for safety analysis. Around 9913 (99.7 %) infants received 2 doses, while 9893 (99.5 %) infants completed all three doses. Total 3693 AEs were reported in 2516 (25.3 %) participants. Most of these AEs were pyrexia (78.01 % of events) and injection-site reactions (19.14 % of events). Nearly all AEs were causally unrelated to orally administered ROTASIIL and could be caused by the concomitant injectable vaccines. Only 4 AEs (2 events of vomiting and 1 event each of discomfort and pyrexia) in 4 (<0.1 %) participants could be related to ROTASIIL. AEs were of mild or moderate severity and all resolved without any sequelae. A total of 2 SAEs (acute otitis media and skull fracture) were reported in 2 (<0.1 %) participants and were not related to ROTASIIL and recovered without sequelae. No case of IS was reported. INTERPRETATION: ROTASIIL was safe and well tolerated in this study. No safety concerns were reported. FUNDING: The study was funded by SIIPL which is the manufacturer of the study product.
format Online
Article
Text
id pubmed-10430202
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104302022023-08-17 Post-marketing safety surveillance of the rotavirus vaccine in India Kang, Gagandeep Lakhkar, Anand Bhamare, Chetanraj Dharmadhikari, Abhijeet Narwadkar, Jyoti Kanujia, Arti Desai, Sajjad Gunale, Bhagwat Poonawalla, Cyrus S. Kulkarni, Prasad S. Vaccine X Regular paper BACKGROUND: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India. METHODS: Observational, active PMS was conducted in approximately 10,000 infants aged ≥ 6 weeks. ROTASIIL was administered as a 3-dose regimen, at least 4 weeks apart, beginning at ≥ 6 weeks of age concomitantly with other Expanded Programme on Immunization (EPI) vaccines. Participants were followed for one month after the last dose. The adverse events (AEs) and serious adverse events (SAEs), including intussusception (IS) reported during the follow up period were collected. FINDINGS: A total of 9940 infants were enrolled and were considered for safety analysis. Around 9913 (99.7 %) infants received 2 doses, while 9893 (99.5 %) infants completed all three doses. Total 3693 AEs were reported in 2516 (25.3 %) participants. Most of these AEs were pyrexia (78.01 % of events) and injection-site reactions (19.14 % of events). Nearly all AEs were causally unrelated to orally administered ROTASIIL and could be caused by the concomitant injectable vaccines. Only 4 AEs (2 events of vomiting and 1 event each of discomfort and pyrexia) in 4 (<0.1 %) participants could be related to ROTASIIL. AEs were of mild or moderate severity and all resolved without any sequelae. A total of 2 SAEs (acute otitis media and skull fracture) were reported in 2 (<0.1 %) participants and were not related to ROTASIIL and recovered without sequelae. No case of IS was reported. INTERPRETATION: ROTASIIL was safe and well tolerated in this study. No safety concerns were reported. FUNDING: The study was funded by SIIPL which is the manufacturer of the study product. Elsevier 2023-08-01 /pmc/articles/PMC10430202/ /pubmed/37593522 http://dx.doi.org/10.1016/j.jvacx.2023.100362 Text en © 2023 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular paper
Kang, Gagandeep
Lakhkar, Anand
Bhamare, Chetanraj
Dharmadhikari, Abhijeet
Narwadkar, Jyoti
Kanujia, Arti
Desai, Sajjad
Gunale, Bhagwat
Poonawalla, Cyrus S.
Kulkarni, Prasad S.
Post-marketing safety surveillance of the rotavirus vaccine in India
title Post-marketing safety surveillance of the rotavirus vaccine in India
title_full Post-marketing safety surveillance of the rotavirus vaccine in India
title_fullStr Post-marketing safety surveillance of the rotavirus vaccine in India
title_full_unstemmed Post-marketing safety surveillance of the rotavirus vaccine in India
title_short Post-marketing safety surveillance of the rotavirus vaccine in India
title_sort post-marketing safety surveillance of the rotavirus vaccine in india
topic Regular paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430202/
https://www.ncbi.nlm.nih.gov/pubmed/37593522
http://dx.doi.org/10.1016/j.jvacx.2023.100362
work_keys_str_mv AT kanggagandeep postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT lakhkaranand postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT bhamarechetanraj postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT dharmadhikariabhijeet postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT narwadkarjyoti postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT kanujiaarti postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT desaisajjad postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT gunalebhagwat postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT poonawallacyruss postmarketingsafetysurveillanceoftherotavirusvaccineinindia
AT kulkarniprasads postmarketingsafetysurveillanceoftherotavirusvaccineinindia